Skip to main navigation

Menu

About Us
- Our Team
  - Our Chief Innovator
- Our Network
Technology
Pipeline
MEDIA
Investors
Careers
Get In Touch

News Releases

Year

Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules

May 26, 2026

Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition

May 15, 2026

Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference

May 12, 2026

Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy

Apr 09, 2026

Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update

Mar 26, 2026

Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization

Mar 25, 2026

Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results

Mar 19, 2026

Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer

Jan 28, 2026

Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen

Jan 08, 2026

Print Page
Email Alerts
RSS Feeds
Contact IR

Company

About
Careers
Contact

Resources

News
Applications
Technology

San Jose Office

2051 Ringwood Ave. San Jose CA, 95131

© Rani Therapeutics. All Rights Reserved. Rani, Rani Therapeutics, and RaniPill and their corresponding logos are trademarks or registered trademarks of Rani Therapeutics, LLC in the US and other countries.